Small molecule · Agonist of mu-opioid receptor (OPRM1) · developed by Mylan Institutional
ApprovedFDA, Jul 1996
1Registered trials
What is Remifentanil?
Remifentanil is a short-acting mu-opioid receptor agonist with rapid onset and offset, cleared by nonspecific blood and tissue esterases. It is used intravenously as an analgesic during general anesthesia, in the postoperative period, and during monitored anesthesia care, and has been studied for pain relief in labour.
Summary written with AI from the sources listed at the end of this page.
Analgesia during induction and maintenance of general anesthesia
Postoperative analgesia continuation in adults in anesthesia care unit or intensive care setting
Analgesic component of monitored anesthesia care in adults
From the indications section of the FDA label (version of Dec 15, 2025). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.